6. Segment Information
We are currently operating as a single operating segment.
Geographical information
In 2023 and 2024, our continuing operations were mainly located in Belgium, France, the Netherlands, Switzerland and the United States. The revenues from our collaboration partner Gilead represented 87% of our total net revenues from continuing operations in 2024 (nearly 100% in 2023). The remaining 13% of the net revenues in 2024 consisted of supply revenues of the Jyseleca® product to Alfasigma (Italy). The revenues in the entity’s country of domicile are not material.
Following table summarizes our net revenues by destination of customer:
|
Year ended December 31 |
|
|---|---|---|
(thousands of €) |
2024 |
2023 |
United States of America |
266,588 |
665,174 |
Europe |
46,577 |
118,354 |
Total net revenues |
313,165 |
783,528 |
|
|
|
minus: |
|
|
United States of America |
25,802 |
425,466 |
Europe |
11,714 |
118,338 |
Total net revenues from discontinued operations |
37,516 |
543,804 |
|
|
|
United States of America |
240,786 |
239,708 |
Europe |
34,863 |
16 |
Total net revenues from continuing operations |
275,649 |
239,724 |
On December 31, 2024, we held €357.8 million (€323.8 million in 2023) of property, plant and equipment, intangible assets and goodwill distributed as follows:
|
December 31 |
|
|---|---|---|
(thousands of €) |
2024 |
2023 |
Belgium |
95,686 |
56,209 |
France |
5 |
1,438 |
The Netherlands |
239,454 |
251,230 |
Switzerland |
92 |
3,247 |
United States of America |
22,533 |
11,660 |
Total |
357,770 |
323,784 |